Cargando…

Pharmacokinetic Models for FcRn-Mediated IgG Disposition

The objectives were to review available PK models for saturable FcRn-mediated IgG disposition, and to explore an alternative semimechanistic model. Most available empirical and mechanistic PK models assumed equal IgG concentrations in plasma and endosome in addition to other model-specific assumptio...

Descripción completa

Detalles Bibliográficos
Autor principal:	Xiao, Jim J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361741/ https://www.ncbi.nlm.nih.gov/pubmed/22665983 http://dx.doi.org/10.1155/2012/282989

Ejemplares similares

FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye
por: Kim, Hyuncheol, et al.
Publicado: (2009)

FcRn mediated IgG transport by retinal pigment epithelium cells
por: Korthagen, Nicoline M, et al.
Publicado: (2012)

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors
por: Dalakas, Marinos C., et al.
Publicado: (2021)

Abundant Intracellular IgG in Enterocytes and Endoderm Lacking FcRn
por: Mohanty, Sudhasri, et al.
Publicado: (2013)

The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement
por: Brinkhaus, Maximilian, et al.
Publicado: (2022)

Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics
por: Piche-Nicholas, Nicole M., et al.
Publicado: (2017)

Efficient Mucosal Delivery of Vaccine Using the FcRn-Mediated IgG Transfer Pathway
por: Ye, Lilin, et al.
Publicado: (2011)

IgG sialylation occurs via the FcRn-mediated recycling pathway in endothelial cells
por: Glendenning, Leandre M., et al.
Publicado: (2023)

Interactions of IgG1 CH2 and CH3 Domains with FcRn
por: Ying, Tianlei, et al.
Publicado: (2014)

Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses
por: Blumberg, L. J., et al.
Publicado: (2019)

Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes
por: Szikora, Bence, et al.
Publicado: (2017)

The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity
por: Tzaban, Salit, et al.
Publicado: (2009)

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity
por: Abdiche, Yasmina Noubia, et al.
Publicado: (2015)

Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders
por: Ward, E. Sally, et al.
Publicado: (2022)

The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan
por: Chaudhury, Chaity, et al.
Publicado: (2003)

Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model
por: Manook, Miriam, et al.
Publicado: (2021)

Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge
por: Stapleton, Nigel M., et al.
Publicado: (2019)

Characterization of the Rabbit Neonatal Fc Receptor (FcRn) and Analyzing the Immunophenotype of the Transgenic Rabbits That Overexpresses FcRn
por: Catunda Lemos, Ana Paula, et al.
Publicado: (2012)

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
por: Zhou, Yihan, et al.
Publicado: (2023)

Human IgE does not bind to human FcRn
por: Brinkhaus, Maximilian, et al.
Publicado: (2022)

Evidence that FcRn mediates the transplacental passage of maternal IgE in the form of IgG anti‐IgE/IgE immune complexes
por: Bundhoo, A., et al.
Publicado: (2015)

In Translation: FcRn across the Therapeutic Spectrum
por: Qi, Timothy, et al.
Publicado: (2021)

Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
por: Schoch, Angela, et al.
Publicado: (2015)

Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life
por: Gjølberg, Torleif Tollefsrud, et al.
Publicado: (2022)

The Role of FcRn in Antigen Presentation
por: Baker, Kristi, et al.
Publicado: (2014)

FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex–driven autoimmunity
por: Hubbard, Jonathan J., et al.
Publicado: (2020)

Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita
por: Coutinho, Ester, et al.
Publicado: (2021)

Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions
por: Monnet, Céline, et al.
Publicado: (2015)

The Dual Targeting of FcRn and FcγRs via Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune Pathologies
por: Monnet, Céline, et al.
Publicado: (2021)

The Neonatal Fc Receptor (FcRn): A Misnomer?
por: Pyzik, Michal, et al.
Publicado: (2019)

Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
por: Stapleton, Nigel M., et al.
Publicado: (2011)

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study
por: Ling, Leona E., et al.
Publicado: (2018)

The neonatal Fc receptor in cancer FcRn in cancer
por: Cadena Castaneda, Diana, et al.
Publicado: (2020)

Response to “The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma”
por: Xu, Xu Steven, et al.
Publicado: (2017)

Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody
por: Maeda, Atsuhiko, et al.
Publicado: (2017)

FcRn is mother’s milk to allergen tolerance
por: Lambrecht, Bart N.
Publicado: (2018)

Megalin Orchestrates FcRn Endocytosis and Trafficking
por: Dahlke, Eileen, et al.
Publicado: (2022)

Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method
por: Müller, Thomas, et al.
Publicado: (2023)

FcRN receptor antagonists in the management of myasthenia gravis
por: Bhandari, Vinaya, et al.
Publicado: (2023)

Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations
por: Peter, Hans-Hartmut, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qeae8s4g4ja9apjvdm15h6gpks